Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis

References

• Sekigawa I, Yanagida M, Iwabuchi K, et al. Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha antibody therapy. Clin Exp Rheumatol. 2008;26:261–267.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Morimoto S, Fujishiro M, et al. Inhibition of each module of connective tissue growth factor as a potential therapeutic target for rheumatoid arthritis. Autoimmunity. 2016;49:109–114.
   PubMed Web of Science ®Google Scholar
• Nozawa K, Fujishiro M, Kawasaki M, et al. Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11:R174.
   PubMed Web of Science ®Google Scholar
• Nozawa K, Fujishiro M, Kawasaki M, et al. Inhibition of connective tissue growth factor ameliorates disease in a murine model of rheumatoid arthritis. Arthritis Rheum. 2013;65:1477–1486.
   PubMed Web of Science ®Google Scholar
• Takigawa M, Nakanishi T, Kubota S, et al. Role of CTGF/HCS24/ecogenin in skeletal growth control. J Cell Physiol. 2003;194:256–266.
   PubMed Web of Science ®Google Scholar
• Collett-Solberg PF, Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine. 2000;12:121–136.
   PubMed Web of Science ®Google Scholar
• Kawai M, Rosen CJ. The insulin-like growth factor system in bone: basic and clinical implications. Endocrinol Metab Clin North Am. 2012;41:323–333.
   PubMed Web of Science ®Google Scholar
• Guvakova MA. Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol. 2007;39:890–909.
   PubMed Web of Science ®Google Scholar
• Heemskerk VH, Daemen MA, Buurman WA. Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev. 1999;10:5–14.
   PubMed Web of Science ®Google Scholar
• Subramaniam S, Shahani N, Strelau J, et al. Insulin-like growth factor 1 inhibits extracellular signal-regulated kinase to promote neuronal survival via the phosphatidylinositol 3-kinase/protein kinase A/c-Raf pathway. J Neurosci. 2005;25:2838–2852.
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29:535–559.
   PubMed Web of Science ®Google Scholar
• Beltran PJ, Mitchell P, Chung YA, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther. 2009;8:1095–1105.
   PubMed Web of Science ®Google Scholar
• Hailey J, Maxwell E, Koukouras K, et al. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther. 2002;1:1349–1353.
   PubMed Web of Science ®Google Scholar
• Chugh R, Griffith KA, Davis EJ, et al. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015;26:1459–1464.
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004;5:231–239.
   PubMed Web of Science ®Google Scholar
• Bao XH, Takaoka M, Hao HF, et al. Esophageal cancer exhibits resistance a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity. Anticancer Res. 2012;32:2827–2834.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Morimoto S, Fujishiro M, et al. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis. Autoimmunity. 2015;48:251–258.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307–310.
   PubMed Web of Science ®Google Scholar
• La Cava A, Alviggi C, Matarese G. Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med. 2004;82:4–11.
   PubMed Web of Science ®Google Scholar
• Salvi R, Peclat V, So A, et al. Enhanced expression of genes involved in coagulation and fibrinolysis in murine arthritis. Arthritis Res. 2000;2:504–512.
   PubMedGoogle Scholar
• Matsumoto T, Gargosky SE, Iwasaki K, et al. Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol Metab. 1996;81:150–155.
   PubMed Web of Science ®Google Scholar
• Pritchard J, Tsui S, Horst N, et al. Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol. 2004;173:3564–3569.
   PubMed Web of Science ®Google Scholar
• Walsh PT, Smith LM, O'Connor R. Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology. 2002;107:461–471.
   PubMed Web of Science ®Google Scholar
• Bielen A, Box G, Perryman L, et al. Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. Proc Natl Acad Sci USA. 2012;109:E1267–E1276.
   PubMed Web of Science ®Google Scholar
• Sabokbar A, Mahoney DJ, Hemingway F, et al. Non-canonical (RANKL-independent) pathways of osteoclast differentiation and their role in musculoskeletal diseases. Clinic Rev Allerg Immunol. 2016;51:16–26.
   PubMed Web of Science ®Google Scholar
• Toyama S, Tamura N, Haruta K, et al. Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice. Arthritis Res Ther. 2010;12:R92.
   PubMed Web of Science ®Google Scholar
• Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res. 2005;65:10123–10127.
   PubMed Web of Science ®Google Scholar
• Chitnis MM, Yuen JS, Protheroe AS, et al. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008;14:6364–6370.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Dickson MA, LoRusso PM, et al. Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity. Cancer Sci. 2016;107:499–506.
   PubMed Web of Science ®Google Scholar